The manufacturer of telavancin has completed Phase III trials in patients with complicated skin and soft-tissue infections (the ATLAS I and II trials). A new drug application (NDA) was filed with ...
Am J Health Syst Pharm. 2007;64(22):2335-2348. The efficacy of telavancin has been studied in several animal models of infection, including bacteremia, endocarditis, meningitis, and pneumonia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback